Variability of chromosomes 1, 9, and 16 in children with malignant diseases

Hodgkin's disease developing after spontaneous remission of chronic lymphocytic leukemia

We present a 71-year-old patient with chronic lymphocytic leukemia diagnosed 27 years ago. Initially, the disease was staged as Rai II and the patient suffered from secondary immunoglobulin deficiency. Nevertheless, no treatment was necessary at that time. Because of disease progression a single course of chemotherapy was given in 1984. During the following year there was a constant decline of the WBC, accompanied by normalization of the immunoglobulins; both have remained stable ever since that time. However, there was still residual bone marrow infiltration, indicating persisting CLL. In 1993 cervical lymphadenopathy occurred with acute onset. A diagnostic lymphadenectomy revealed Hodgkin's disease of the nodular-sclerosing subtype. The patient was staged as II-III according to the Ann Arbor Classification and underwent radiation therapy. Cytogenetic examination of the bone marrow revealed a normal karyotype with an inversion of chromosome 9. This case demonstrates the rate coincidence of two lymphoproliferative disorders in the same patient. The clinical course and the immunologic findings of this patient are presented, together with a review of the literature.

Cytogenetic findings in 111 ovarian cancer patients: therapy-related chromosome aberrations and heterochromatic variants

The chromosomes of 111 ovarian cancer patients were studied in G- and C-banded slides from peripheral blood lymphocyte (PBL) cultures for chromosome damage caused by chemotherapy and radiotherapy and for asymmetry of the constitutive heterochromatin of chromosomes 1, 9, and 16. We also monitored the survival of these patients to determine whether any secondary neoplasia induced by the therapy and report the findings of our investigations. Melphalan (MEL) was the only drug used in single-drug chemotherapy. The incidence of chromosome abnormalities in melphalan-treated cells (25%) was higher than in the control group (17%). The incidence of structural changes was also higher (10.5%) in the MEL-treated group than in controls (6%). After treatments with combinations of drugs, the incidence of structural changes remained at the same level (11%). In the patients receiving combined treatment with MEL and radiation, the rate of structural changes increased dramatically (24%). The overall rate of chromosome aberrations in this group was also higher (50%). Combination of two or more drugs and radiation produced only 14% structural chromosome changes. The overall rate of chromosome aberrations was also low (20%) in this group. Of 111 patients studied, only 33 were alive 6 years after initiation of the study. Of the surviving patients, eight had rearranged chromosomes in the first analysis. After 5 years, new blood samples were collected from these patients and chromosome analyses showed abnormal karyotypes in all eight patients. All chromosome abnormalities in the second analysis were completely unrelated to those in the first analysis, however. Whether the chromosome changes in the second analysis were due to therapy or to other unknown factors could not be determined. Data on C-banding and the distribution of inversions indicated that 91% of the patients had C-band heteromorphisms of chromosomes 1, 91% had heteromorphisms of chromosome 9, and 69% had heteromorphisms of chromosome 16. Furthermore, inversions were observed in chromosome 1 (41% of patients), chromosome 9 (28% of patients), and chromosome 16 (5% of patients).

Constitutive heterochromatin polymorphisms in children with acute lymphoblastic leukemia

The C-band heterochromatin polymorphisms of chromosomes 1, 9, and 16 were studied on peripheral lymphocytes of 67 children with acute lymphoblastic leukemia (ALL) and 50 control individuals. A statistically significant difference between patients and controls was found for large heterochromatin regions (level 3) of chromosomes 1 and 9 (P < 0.001) and for small heterochromatin regions (level 1) of chromosome 16 (P < 0.001). The patients also showed a significant increase in chromosomes 1 and 9 heteromorphism with respect to controls (P < 0.001).

Heteromorphism of chromosome 1, 9 and 16 homologues in high- and medium-longevity level regions

Regional and age-related peculiarities of chromosomal polymorphism are established as a result of studies in C-band heteromorphism of chromosomes 1, 9 and 16 in the long-lived subjects, their relatives and population groups of the Abkhazian and Ukrainian regions. Heteromorphism frequencies of chromosomes 1 and 9 homologues are high in the Abkhazian as compared with the Ukrainian regions. Age-related differences as to the degree of expression of chromosome 9 C-band heteromorphism found are as follows: in the Abkhazian region the frequency of variants with a high degree of heteromorphism increases with age, while in the Ukrainian region, with a low degree of heteromorphism, it decreases.

Abnormalities of chromosome 1 in relation to human malignant diseases

Chromosome 1 is known to often be involved in various malignant diseases. Its numerical and structural aberrations have been observed in chronic and acute leukemias and solid tumors as well. Recently five protooncogenes have been assigned to the long and short arms of chromosome 1. The frequent and nonspecific occurrence of chromosome 1 rearrangements in human tumors suggests that they play an important role in the pathogenesis and progression of these diseases. The frequency, types, and time of the occurrence of chromosome 1 aberrations and their relation to the stage of the disease were studied in 317 patients with various malignant diseases. In ten patients nonrandom aberrations of chromosome 1 were observed. Two patients had CML, two PRV followed by ANLL, and the remaining six patients suffered from ANLL, ALL, Burkitt lymphoma, MF, SMMoL, and IRSA, respectively. In six patients, total or partial trisomy of the long arm or of the whole chromosome 1 was present, and in three cases balanced translocations involving chromosome 1 could be found. In the cells of one patient a duplication of the centromeric heterochromatin was seen. We analyzed the breakpoints involved. Finally, the aberrations of chromosome 1 were almost always be observed at the terminal stage of the diseases.

Densitometric measurements of C bands of chromosomes 1, 9, 16, and Y in leukemic and preleukemic disorders

Fifty-six patients with blood disorders (23 with chronic myeloid leukemia, 14 with acute myeloblastic leukemia, seven with acute lymphoblastic leukemia, one with chronic lymphocytic leukemia, and 11 with preleukemia states) were studied. A quantitative and objective method of C band length analysis with well-matched controls was used. The C bands of chromosome pairs 1, 9, and 16 presented a normal distribution that was similar in patients and controls, whereas the Y chromosome presented an abnormal distribution. Smaller C bands in 1qh and higher indexes of intrapair heteromorphism in pairs 1 and 9 were detected in the CML group; the group of acute leukemias (myeloblastic and lymphoblastic) presented a smaller index only in pair 1qh. No other differences in length, heteromorphism, inversion frequency, or sex were detected.

C-band polymorphisms in lymphocytes of patients with ovarian or breast adenocarcinoma

To establish the significance of the variability of human chromosome constitutive heterochromatin areas (C-band variants) in a risk of malignancy, C-banding pattern study has been performed in 33 female patients with ovarian or breast adenocarcinoma. The control group included 180 healthy women. The following characteristics of C-bands on chromosomes #1, #9, and #16 were studied: (a) size, (b) size heteromorphisms and (c) inversions, using quantitative and semiquantitative methods of analysis. Our data show no significant difference in the presence of C-band size and location variants in chromosomes #1, #9, and #16 between the patients with adenocarcinoma of the ovary or breast and healthy women. From that we conclude that there is no causal association between the presence of C-band variants on chromosomes #1, #9, and #16 and an elevated risk of ovarian and breast adenocarcinoma.

Polymorphism of heterochromatin areas on chromosomes 1, 9, 16 and Y in long-lived subjects and persons of different ages in two regions of the Soviet Union

Variants of chromosome polymorphism were analyzed in long-lived individuals and in subjects aged 40-79 years (170 persons) in two regions of the Soviet Union. The results of this analysis allow the suggestion that there is an association between the individual variants of chromosome polymorphism as regards C heterochromatin and the longevity phenomenon. Large size C segments on the human Y chromosome and the long Y chromosome were found both in the Ukrainian and Abkhasian long-lived males. In the long-lived females the chromosome polymorphism variants were associated with a region of their residence. The long-lived females of Abkhasia had a decreased relative size of C segments on chromosome 1 and an increased absolute and relative size of C segments on chromosome 9, while in their Ukrainian counterparts there was an increased relative size of C segments on chromosome 1 and a decreased one on chromosome 16.

Constitutional interstitial deletion of 11p11 and pericentric inversion of chromosome 9 in a patient with Wiedemann-Beckwith syndrome and hepatoblastoma

A constitutional interstitial deletion on the short arm of chromosome #11 and an inversion of the heterochromatin of chromosome #9 were detected in a 1.5-year-old boy with Wiedemann-Beckwith syndrome (WBS) and hepatoblastoma. Of 37 malignant and nine benign neoplasms reported in approximately 250 cases with complete and incomplete forms of WBS, this is the fourth patient with hepatoblastoma. To date, 28 cases of WBS have been cytogenetically investigated with banding techniques. Constitutional anomalies have been found in only nine cases: Various anomalies resulting in a common triplication of the 11p15 region in six cases, reciprocal translocations t(11;22) and t(X;1) and an inversion of chromosome #2 in the three remaining cases. Triplication 11p15 was only present in one of four cases with a tumor. The breakpoints of the unique del(11)(p11.1p11.2) present in our case are proximal to those of del(11p13-11p14) and dup(11p15) observed thus far in both the aniridia-Wilms' tumor association and in WBS. Inversion of chromosome #9--one of the heterochromatin variants associated with elevated chromosomal instability, increased congenital abnormalities, and cancer proneness--may have been causally connected with a genetic imbalance resulting in the de novo deletion of 11p11. Therefore, we suggest that in these high-risk groups, C-banding studies should be performed together with high resolution chromosome analysis in order to also reveal the incidence and significance of C-band variants in individuals with such cancer prone syndromes.

Constitutive heterochromatin studies in patients with solid tumors

Constitutive heterochromatin of chromosomes 1, 9, and 16 was studied in 101 patients with solid tumors and 85 controls. Lymphocyte cultures were used for performing C-banded chromosome preparations. Two homologous chromosomes were regarded as heteromorphic when there was a 25% difference between their C-band size or when they fell into different classes according to the method of Patil and Lubs (1977). A statistically significant difference between patients and controls was found in chromosome 1 heteromorphism. No statistical difference between patients and controls was found in the heteromorphism of chromosomes 9 and 16. The frequencies with which pericentric inversions of the heterochromatin in chromosomes 1 and 9 occurred in cancer patients were 9.9% and 12.9%, respectively. Patients displaying this type of polymorphism usually showed an increased rate of chromosome associations. The most frequent associations were found between heterochromatic regions of chromosomes 1 and 9 and between the chromosome 9 heterochromatin and D acrocentrics. These results support the hypothesis concerning the involvement of constitutive heterochromatin of chromosome 1 in malignant disease.